Janos L. Tanyi

Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania

Attending Physician, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

Department: Obstetrics and Gynecology

Contact information

Department of Obstetrics and Gynecology
Jordan Center for Gynecologic Cancer at Penn
Perelman Center for Advanced Medicine
3400 Civic Center Boulevard, 3 West
Philadelphia, PA 19104

Office: 215-662-3318
Fax: 215-349-5849

Email:
janos.tanyi@uphs.upenn.edu

Education:
M.D. (Summa cum Laude)
University of Debrecen, Faculty of Medicine, Hungary , 1993.
Ph.D. (Summa cum Laude)
Semmelweis University, Faculty of Medicine, School of Clinical Sciences, Budapest, Hungary, 2008.

Post-Graduate Training
Residency Training, Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary, 1993-1998.
Postdoctoral Fellow and Research Scholar, University of Texas, MD Anderson Cancer Center, Houston, TX, 1999-2004.
Resident, Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, 2004-2008.
Fellow, Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2008-2011.

Permanent link

> Perelman School of Medicine > Faculty > Details

Selected Publications

de Santiago PR, Sato S, Zhang SJ, Dougher MC, Devins KM, Bilecz AJ, Rayamajhi S, Mingo G, Rendulich HS, Feng Y, Wu C, Taylor MS, Zhuravlev Y, Jung E, Omran DK, Wang TL, Shih IM, Schwartz LE, Kim S, Morgan MA, Tanyi JL, Burns KH, Lengyel E, Parra-Herran C, Godwin AK, Walt DR, Drapkin R : LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker. NPJ Precis Oncol Mar 2025.

Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA.: Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med Jan 2025.

Sande CM, Erráez-Jaramillo PJ, Zhang Q, Suresh K, Hicks-Courant K, Tanyi JL, Zhang PJ.: Giant Angiomyofibroblastoma With a Florid Lipomatous Component: A Report and Review of Diagnostic Considerations. Int J Surg Pathol Nov 2024.

Li S, Oatman E, Tanyi J, Kim SH, Cory L, Mangalmurti NS.: Detection of HPV DNA on Red Blood Cells. Oral presentation. Mid-Atlantic Gynecologic Oncology Society Conference. Atlanta, GA. Oct 2024.

Tanyi JL, O’Hara M, Hexner E, Marshall A, Jadlowsky J, Farrelly O, Carly Stein C, Anne Chew A, Emily Dowd E, Vanessa Gonzalez V, Joseph Fraietta J, Gabriela Plesa G, Neil Sheppard N, Carl June C.: Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (HuCART-meso) Administered in Combination with VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer. Oral Presentation. Advancing Gene and Cell Therapies for Cancer Conference. Philadelphia, PA Oct 2024.

Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL.: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study. Ann Surg Oncol Jul 2024.

Pohlmann P R, Abdou Y, Johnson M, Maziarz RT, Specht J, Dees E Claire, Yuan Y, Tanyi J, Angelos M, Gill S, Wetzel J, Cushing D, Klichinsky M, Condamine T, and Reiss K: A Phase 1, First in Human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors. ASCO Chicago, IL (TIP- Trail in progress) Jun 2024.

Simpkins F, Nasioudis D, Wethington S, Martin L. Tanyi, J, Latif N, Torigian D, Omran D, Rodriguez D, Smith S, Dean E, Domchek S, Drapkin R, Shih I, Brown, E, Hwang W, Armstrong D, Gaillard S, Giuntoli R, Liu J: Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). ASCO, 2024, Annual Meeting. Chicago, IL Jun 2024.

Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Huang J, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi JL, Tavana O, Chan HM, Hu X, Zhang L.: Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. bioRxiv May 2024.

Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL.: ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from a Phase 2 Study. Ann Surg Oncol. Page: doi: 10.1245/s10434-024-15307-8. Online ahead of print, May 2024.